| Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ... Breast Cancer Research 15, 1-37, 2013 | 542 | 2013 |
| Bone metastases RE Coleman, J Brown, I Holen Abeloff's clinical oncology, 809-830. e3, 2020 | 523 | 2020 |
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ... Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001 | 461 | 2001 |
| Tumour macrophages as potential targets of bisphosphonates TL Rogers, I Holen Journal of translational medicine 9, 1-17, 2011 | 398 | 2011 |
| Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells I Holen, PI Croucher, FC Hamdy, CL Eaton Cancer research 62 (6), 1619-1623, 2002 | 370 | 2002 |
| Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway M Coscia, E Quaglino, M Iezzi, C Curcio, F Pantaleoni, C Riganti, I Holen, ... Journal of cellular and molecular medicine 14 (12), 2803-2815, 2010 | 338 | 2010 |
| Exploring the anti-tumour activity of bisphosphonates in early breast cancer MC Winter, I Holen, RE Coleman Cancer treatment reviews 34 (5), 453-475, 2008 | 290 | 2008 |
| Bone metastasis: mechanisms, therapies, and biomarkers P Clézardin, R Coleman, M Puppo, P Ottewell, E Bonnelye, F Paycha, ... Physiological reviews 101 (3), 797-855, 2021 | 289 | 2021 |
| Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer PD Ottewell, H Mönkkönen, M Jones, DV Lefley, RE Coleman, I Holen Journal of the National Cancer Institute 100 (16), 1167-1178, 2008 | 280 | 2008 |
| Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies NS Wind, I Holen International journal of breast cancer 2011 (1), 967419, 2011 | 246 | 2011 |
| In vivo models in breast cancer research: progress, challenges and future directions I Holen, V Speirs, B Morrissey, K Blyth Disease models & mechanisms 10 (4), 359-371, 2017 | 240 | 2017 |
| IL-1 drives breast cancer growth and bone metastasis in vivo I Holen, DV Lefley, SE Francis, S Rennicks, S Bradbury, RE Coleman, ... Oncotarget 7 (46), 75571, 2016 | 218 | 2016 |
| Sequence‐and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells HL Neville‐Webbe, A Rostami‐Hodjegan, CA Evans, RE Coleman, ... International journal of cancer 113 (3), 364-371, 2005 | 208 | 2005 |
| Dependence of hepatocytic autophagy on intracellularly sequestered calcium. PB Gordon, I Holen, M Fosse, JS Røtnes, PO Seglen Journal of Biological Chemistry 268 (35), 26107-26112, 1993 | 207 | 1993 |
| Optimizing the yield and utility of circulating cell-free DNA from plasma and serum X Xue, MD Teare, I Holen, YM Zhu, PJ Woll Clinica chimica acta 404 (2), 100-104, 2009 | 204 | 2009 |
| Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel P Hadji, RE Coleman, C Wilson, TJ Powles, P Clézardin, M Aapro, ... Annals of Oncology 27 (3), 379-390, 2016 | 197 | 2016 |
| The breast tumor microenvironment: role in cancer development, progression and response to therapy S Mittal, NJ Brown, I Holen Expert review of molecular diagnostics 18 (3), 227-243, 2018 | 189 | 2018 |
| Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo PD Ottewell, N Wang, HK Brown, KJ Reeves, CA Fowles, PI Croucher, ... Clinical Cancer Research 20 (11), 2922-2932, 2014 | 181 | 2014 |
| Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment C Tulotta, DV Lefley, K Freeman, WM Gregory, AM Hanby, PR Heath, ... Clinical Cancer Research 25 (9), 2769-2782, 2019 | 168 | 2019 |
| Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival? I Holen, SS Cross, HL Neville-Webbe, NA Cross, SP Balasubramanian, ... Breast cancer research and treatment 92, 207-215, 2005 | 166 | 2005 |
Robert ColemanUniversity of SheffieldVerifisert e-postadresse på sheffield.ac.uk